跳至主要内容
临床试验/NL-OMON50801
NL-OMON50801已完成不适用

Pancreatic cancer surveillance in CDKN2A and other high risk mutation carriers - PARSEC

eids Universitair Medisch Centrum0 个研究点目标入组 280 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must be
  • participating in the LUMC PC surveillance program, which requires:
  • - aged between 40 and 75, and
  • i) a proven CDKN2A or LKB1/STK11 mutation, regardless of family history, or
  • ii) a BRCA1/2, PALB2, ATM, MLH1/MSH2/MSH6 mutation with at least one first
  • degree relative with PC.

排除标准

  • - Comorbidity leading to an impaired physical performance (World health
  • organization (WHO) performance status 3-4) or mental retardation.
  • - Life expectancy <5 years
  • - Very limited understanding of the Dutch or English language to be able to
  • make an informed choice.
  • - No informed consent.

研究者

相似试验